Ofer Agid
YOU?
Author Swipe
View article: Placebo versus no treatment for people with schizophrenia: A systematic review and meta‐analysis
Placebo versus no treatment for people with schizophrenia: A systematic review and meta‐analysis Open
View article: The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment
The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment Open
This expert consensus panel provided recommendations to guide HCPs on how to overcome barriers to LAI use and to implement, monitor, and maintain LAIs as routine schizophrenia treatment.
View article: RESIDUAL SYMPTOMS IN MAJOR DEPRESSIVE DISORDER: CLINICAL UTILITY OF VENLAFAXINE
RESIDUAL SYMPTOMS IN MAJOR DEPRESSIVE DISORDER: CLINICAL UTILITY OF VENLAFAXINE Open
Background Major depressive disorder (MDD) results in functional impairment that reduces quality of life. The current definition of clinical remission in MDD does not encompass functional recovery (Yang 2022). Anhedonia, amotivation, low e…
View article: Challenges for switching central nervous system and psychiatric medication products: A review of the literature
Challenges for switching central nervous system and psychiatric medication products: A review of the literature Open
Background: Switching between versions of medication products happens commonly despite challenges in achieving bioequivalence and therapeutic equivalence. Central nervous system and psychiatric drugs, especially those that are technically …
View article: Clinical Correlates of Antipsychotic Plasma Levels with Long-Acting Paliperidone: Corrélats cliniques des concentrations plasmiques de palipéridone à libération prolongée
Clinical Correlates of Antipsychotic Plasma Levels with Long-Acting Paliperidone: Corrélats cliniques des concentrations plasmiques de palipéridone à libération prolongée Open
Objectives The majority of patients with schizophrenia experience dramatic improvement in psychotic symptoms when treated with antipsychotic medication. Maintenance treatment can prevent relapses but problems with medication adherence limi…
View article: Re-evaluating the prognosis of schizophrenia: tackling the issue of inadequate treatment
Re-evaluating the prognosis of schizophrenia: tackling the issue of inadequate treatment Open
View article: Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice
Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice Open
View article: Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol
Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol Open
Schizophrenia spectrum disorders (SSDs) are associated with significant functional impairments, disability, and low rates of personal recovery, along with tremendous economic costs linked primarily to lost productivity and premature mortal…
View article: Clozapine Optimization: A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group
Clozapine Optimization: A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group Open
Background and Hypothesis There is limited evidence to guide the approaches to clozapine treatment. Accordingly, an international initiative was undertaken with the aim of developing consensus recommendations for the optimization of clozap…
View article: Placebo versus no treatment for people with schizophrenia
Placebo versus no treatment for people with schizophrenia Open
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To compare the effects of placebo versus no treatment in people with schizophrenia.
View article: Effect of venlafaxine on anhedonia and amotivation in patients with major depressive disorder
Effect of venlafaxine on anhedonia and amotivation in patients with major depressive disorder Open
View article: Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia Open
View article: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia Open
View article: When No Treatment Is the Treatment: Mental Illness–Related Case Report
When No Treatment Is the Treatment: Mental Illness–Related Case Report Open
View article: Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study
Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study Open
Objective: The objective of this study was to analyze the real-world prevalence of long-acting injectable (LAI) antipsychotic use and determine when LAIs are being used in sequencing of antipsychotic medications among Canadian patients wit…
View article: Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia
Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia Open
View article: Antipsychotic Medications: Enhancing Use to Improve Outcomes
Antipsychotic Medications: Enhancing Use to Improve Outcomes Open
View article: The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research
The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research Open
(Reprinted with permission from NPJ Schizophrenia (2020) 6:1).
View article: Correction to: The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
Correction to: The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey Open
An amendment to this paper has been published and can be accessed via the original article.
View article: The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey Open
Background It is well established that the different antipsychotics used for schizophrenia symptoms differ substantially in their side effects. However, relatively little is known about the impact of these side effects on functioning from …
View article: Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis
Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis Open
Little is known regarding optimal antipsychotic doses in the acute phase of schizophrenia. The aim of the present study was to employ the concept of minimum effective dose (MED) in examining efficacy and tolerability within this population…
View article: The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research
The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research Open
Treatment-resistant schizophrenia (TRS), the persistence of positive symptoms despite ≥2 trials of adequate dose and duration of antipsychotic medication with documented adherence, is a serious clinical problem with heterogeneous presentat…
View article: Caregiver Burdens Associated With Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes, and Perceptions
Caregiver Burdens Associated With Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes, and Perceptions Open
Background: Previous qualitative studies indicate high caregiver burden associated with providing care for people with treatment-resistant schizophrenia (TRS). In this study, we report the first quantitative data to characterize the burden…
View article: F33. MODELLING THE PREDICTORS OF EFFORT-BASED DECISION-MAKING IN SCHIZOPHRENIA
F33. MODELLING THE PREDICTORS OF EFFORT-BASED DECISION-MAKING IN SCHIZOPHRENIA Open
Motivation deficits and reduced goal-directed behaviour are prominent in schizophrenia (SZ), and significantly contribute to poor functional and treatment outcomes. One of the critical components of the multi-faceted motivation system is e…
View article: Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia
Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia Open
View article: S76. A BEHAVIOURAL ECONOMIC ANALYSIS OF EFFORT-RELATED CHOICE IN SCHIZOPHRENIA
S76. A BEHAVIOURAL ECONOMIC ANALYSIS OF EFFORT-RELATED CHOICE IN SCHIZOPHRENIA Open
S354Poster Session IIIEvidence suggests that several factors may influence the development of paranoia, including social cognitive biases such as diminished trust, increased hostility, and increased tendency to blame others (Pinkham et al.…
View article: F121. DOES RELAPSE CONTRIBUTE TO TREATMENT RESISTANCE? ANTIPSYCHOTIC RESPONSE IN FIRST- VS. SECOND-EPISODE SCHIZOPHRENIA
F121. DOES RELAPSE CONTRIBUTE TO TREATMENT RESISTANCE? ANTIPSYCHOTIC RESPONSE IN FIRST- VS. SECOND-EPISODE SCHIZOPHRENIA Open
The objective of this study was to compare trajectories of antipsychotic response before and after relapse following response from a first episode of schizophrenia or schizoaffective disorder. The current analysis included patients with a …
View article: S229. CAN LONG-ACTING INJECTABLE PALIPERIDONE DOSING BE OPTIMIZED WITH PLASMA LEVEL MEASUREMENTS?
S229. CAN LONG-ACTING INJECTABLE PALIPERIDONE DOSING BE OPTIMIZED WITH PLASMA LEVEL MEASUREMENTS? Open
BACKGROUND: Most people with schizophrenia respond robustly to antipsychotic medication but are at very high risk of relapse if these medications are stopped. Long-term maintenance treatment with antipsychotic medication can dramatically r…
View article: One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis
One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis Open
Background As definitions of relapse differ substantially between studies, in investigations involving data aggregation, total scores on clinical rating scales provide a more generalisable outcome. Aims To compare total symptom trajectorie…
View article: SA109. Examining Reward Responsiveness and Expectancy Across a Dimension of Motivation Deficits in Schizophrenia
SA109. Examining Reward Responsiveness and Expectancy Across a Dimension of Motivation Deficits in Schizophrenia Open
\nBackground: Anhedonia has long been associated with schizophrenia (SZ); however, the true nature of this deficit remains elusive. Given the role of hedonic capacity within the larger motivational framework, we sought to examine reward re…